“If you don’t like it, come up with a better solution,” proponents of the transferable exclusivity voucher scheme said at a webinar on tackling antimicrobial resistance.
The European Commission’s proposal to use transferable exclusivity vouchers as a way of encouraging companies to develop new antimicrobial drugs has drawn praise and criticism in equal measure.
For some, the idea is the best way to fix the “broken” antimicrobial business model, while others say it would...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
